Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MS1819-SD + pancreatic pork enzymes
- Development stage
- Unknown
- Lead developer
- Entero Therapeutics
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
**MS1819-SD + pancreatic pork enzymes** is a combination therapy under investigation for the treatment of exocrine pancreatic insufficiency (EPI), particularly in patients with cystic fibrosis or chronic pancreatitis. MS1819-SD is a recombinant lipase derived from the yeast Yarrowia lipolytica, formulated as an oral biologic enzyme replacement lacking animal-derived components. Pancreatic pork enzymes, also called porcine pancreatic enzyme replacement therapy (PERT), are standard-of-care enzyme supplements extracted from pig pancreas and contain a mixture of lipases, amylases, and proteases to aid digestion. This combination aims to augment digestive function where standard PERT is insufficient, with MS1819-SD providing non-animal-derived lipase activity and porcine enzymes delivering a broader enzyme spectrum. The combination is being evaluated for safety and efficacy in clinical trials, particularly for cystic fibrosis-related EPI not fully managed by PERT[1][2][3][5][7].
- Other names
- MS1819-SD + porcine pancreatic enzymesMS1819-SD plus PERTMS-1819-SD plus PERTMS 1819-SD plus PERT
Beyond the preview
Go deeper on MS1819-SD + pancreatic pork enzymes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MS1819-SD + pancreatic pork enzymes.